OK, I might agree with you that the pps could double, but for which company? Or do you really believe both of them would double? I know that SPPI gets royalties of 10% and that GPCB would be the main beneficiary of approval (they now own the drug, although I understand it's being contested by SPPI - maybe they just want a bigger percentage in the way of royalties since they screwed up in "giving" it away) - but I'm not sure if I would think that both might double. Care to provide your rationale on the double and which company, or why both?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.